Quebec-Based COVID Vaccine Manufacturer to Halt All Operations

A vial of a plant-derived COVID-19 vaccine candidate, developed by Medicago, is shown in Quebec City on July 13, 2020, as part of the company’s Phase 1 clinical trials. The Canadian Press/HO, Medicago

A COVID-19 vaccine manufacturing company in Quebec is set to cease all operations after its owner and sole shareholder decided to pull investments because of “significant changes” in the COVID vaccine-making industry.

Medicago Inc., which is headquartered in Quebec City and was the manufacturer of the plant-based COVID vaccine, Covifenz, announced on Feb. 3 that it will not be receiving any further investments from the Mitsubishi Chemical Group (MCG) and that it will now begin an “orderly wind-up of its business and operations in Canada and in the United States.”